The Quadrivalent Subunit Influenza Vaccine is developed using the company's own patented technology and is in phase III clinical trial. It has the characteristics of high purity and good safety, especially suitable for children. Currently, no such products are available on the market at home and abroad.

This product uses the truncated VZV gE protein with independent intellectual property rights of our company as the antigen, and contains major B-cell and T-cell epitopes. Equipped with the self-developed dual adjuvant system, it can induce the body to produce strong specific humoral and cellular immune responses. All adjuvants used have been applied in marketed vaccines.